VKTX - Viking Therapeutics: Here To Stay In Obesity Or A Flash In The Pan?

2024-03-08 08:00:00 ET

Summary

• Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug.
• Eli Lilly and Novo Nordisk have major potential in the obesity market with their drugs semaglutide and tirzepatide - their share prices are +500% and +400% over a 5-year period.
• Viking Therapeutics is challenging the supremacy of Eli Lilly and Novo Nordisk with potentially best-in-class data for its drug VK2735, which has a similar mechanism of action.
• Lilly and Novo are expected to dominate a market that could reach $150bn in size - VKTX has the opportunity to become the third player - upcoming data readouts will be critical to determining if its candidate is the "real deal"

Investment Overview

Viking Therapeutics ( VKTX ) stock exploded in value last week as the company released positive data from a Phase 2 stage clinical study of its dual GLP-1/GIP receptor agonist VK2735 in patients with obesity.

This week, however, its stock price has been falling, as Danish Pharma giant Novo Nordisk ( NVO ) shared Phase 1 clinical study data from a new oral weight loss pill, suggesting it could the most effective obesity treatment to date....

For further details see: